Skip to main content
Midas Edge

Ainos, Inc.

For the period ended Sep 24, 2026. Filed Sep 28, 2026.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Sep 24, 2026 · Filed Sep 28, 2026

AIMD$0.70+11.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.1 · Reference

Reference

[1] Okada, N. and Takahashi, Y. “Cost and Duration of Clinical Trials in Drug Development by Japanese Pharmaceutical Companies.”Pharmaceutical Medicine 39, 199–207 (2025). Dollar equivalents use the study’s reference exchange rate of JPY 109 per U.S. dollar. The approximately $54 million figure adds separate phase-specific medians; it is not an observed median total development cost. Source.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.